export default function FiveAmino1MQOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        5-Amino-1MQ is an oral research compound that inhibits an enzyme called NNMT, which is overactive in obese fat tissue and consumes cellular energy currency. By blocking this enzyme, the compound raises two metabolic molecules simultaneously and may shift fat cells toward burning more energy. The mouse data showing fat loss without caloric restriction is real. There are no published human clinical trials. Community use is running well ahead of the science.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Weight Loss Person &mdash; Looking for something that works on metabolism</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve read about this compound that supposedly makes fat cells burn more energy even without dieting. The mouse studies look compelling. Is this real or is it just another overhyped supplement?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The premise is genuinely different from appetite suppression</strong><br />Most weight loss tools work by reducing how much you eat &mdash; GLP-1 drugs, stimulants, fiber, behavioral approaches. 5-Amino-1MQ is targeting something different: the metabolic programming of fat cells themselves. The mouse data suggested fat loss with free food access, which is the kind of result that makes people sit up. If it translates to humans, it would represent a mechanistically distinct intervention.</li>
          <li><strong>It&rsquo;s oral, which removes injection as a barrier</strong><br />Unlike most research compounds in the weight/metabolic space that require subcutaneous injection, 5-Amino-1MQ is taken orally. For people who are interested in exploring research compounds but are uncomfortable with injections, this is a meaningful practical consideration.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Mouse fat loss studies have a very poor track record of translating to humans. Mouse metabolism is profoundly different from human metabolism in ways that matter enormously for a compound targeting metabolic programming. There are no published human clinical trials with 5-Amino-1MQ &mdash; not small ones, not preliminary ones, zero. Community reports of body composition changes over months of use cannot be separated from concurrent diet, exercise changes, and expectation effects without controlled conditions. The research chemical supply chain for this compound is less mature than for more established peptides, which means product quality is more variable. Net: mechanistically interesting premise, no human evidence, and product quality uncertainty &mdash; calibrate expectations accordingly.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete Cutting &mdash; Preserving muscle while reducing body fat</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;m in a cutting phase and I&rsquo;m looking at tools that might shift my body composition without tanking performance. The NAD+ angle is interesting to me &mdash; does this actually do anything useful for athletes?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The NAD+ elevation angle has genuine athlete appeal</strong><br />NAD+ is essential for cellular energy production and is consumed rapidly during high-intensity exercise. Compounds that raise NAD+ are discussed in performance contexts because of their potential to support mitochondrial function and reduce cellular fatigue. 5-Amino-1MQ raises NAD+ by blocking the enzyme that depletes it &mdash; a different approach from NAD+ precursor supplementation.</li>
          <li><strong>The fat cell metabolic programming angle could theoretically benefit body composition</strong><br />If fat cells in adipose tissue become metabolically more active &mdash; burning more energy rather than storing it &mdash; that would theoretically support a caloric deficit goal during a cut. The mechanism doesn&rsquo;t suppress appetite or force compliance with a diet; it would be working at a tissue level independently of behavior.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">There is no human data quantifying any of these effects &mdash; not the NAD+ elevation, not the fat cell metabolic shift, not the body composition outcome. Stacking a compound with no human evidence alongside training and nutrition makes attribution of any result to 5-Amino-1MQ essentially impossible. The methylation pathway effects &mdash; SAM is involved in epigenetic regulation &mdash; are not characterized in the context of exercise physiology at all. Athletes in competition should note that this compound&rsquo;s WADA status is unclear given its research-chemical classification. Net: the theoretical angles are interesting for an athlete, but the evidence gap means you&rsquo;d be running a personal experiment with an unknown outcome.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Metabolic Optimization Biohacker &mdash; NNMT biology, NAD+ pathways, epigenetic angles</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand the NNMT biology in depth &mdash; specifically how it interacts with the NAD+ precursor pool, the SAM methyl donor system, and what the downstream epigenetic effects of NNMT inhibition might actually be.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>NNMT sits at a genuinely interesting metabolic crossroads</strong><br />NNMT methylates nicotinamide using SAM as the methyl donor &mdash; consuming both SAM and diverting nicotinamide away from NAD+ synthesis. Inhibiting it simultaneously raises NAD+ (by sparing nicotinamide for the salvage pathway) and raises SAM (by not consuming the methyl donor). These are two separate metabolic pools with major downstream effects: NAD+ feeds sirtuins and PARP; SAM feeds methyltransferases that regulate gene expression. The convergence on both systems from a single enzyme inhibition is mechanistically unusual.</li>
          <li><strong>NNMT is elevated in obese adipose tissue &mdash; it may be a driver, not just a correlate</strong><br />NNMT activity is consistently elevated in visceral adipose tissue from obese individuals and in mice on high-fat diets. The mouse data showing that NNMT inhibition prevents diet-induced obesity and reverses established obesity suggests this is not just a correlate of the obese state but potentially a mechanistic driver. The adipose-specific metabolic phenotype change &mdash; fat cells becoming more thermogenically active &mdash; is consistent with the NNMT expression pattern in that tissue.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">NNMT is not adipose-tissue-specific &mdash; it is also highly expressed in liver, and its roles in hepatic methylation metabolism are not fully characterized. Long-term NNMT inhibition could affect homocysteine metabolism (SAM/SAH balance affects the trans-sulfuration pathway), hepatic one-carbon metabolism, and tissue-specific epigenetic programming in ways that are not characterized for any chronic dosing duration. The community protocols for 5-Amino-1MQ are essentially invented &mdash; there are no human dose-finding studies, no human pharmacokinetic studies, and no human safety studies. Comparing this to NMN or NR supplementation: those at least have small human trials; 5-Amino-1MQ has none. Net: the mechanism is genuinely interesting as a research area, but the human translational gap is enormous and the systemic consequences of long-term NNMT inhibition in humans are genuinely unknown.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What 5-Amino-1MQ is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not a proven fat loss compound in humans &mdash; the mouse data is real, human data does not exist</li>
              <li>Not equivalent in evidence to semaglutide, berberine, or even NMN for metabolic goals</li>
              <li>Not a peptide &mdash; it is a small molecule quinolinium salt that happens to be sold alongside peptides in the research compound community</li>
              <li>Not appropriate for anyone with active liver disease &mdash; NNMT is highly expressed in liver and the metabolic consequences of inhibition in a diseased liver are unknown</li>
              <li>Not proven safe over any meaningful time period &mdash; no long-term human safety data exists at all</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>Mechanistically distinct from every other weight loss compound &mdash; it targets fat cell metabolic programming, not appetite or caloric restriction</li>
              <li>Inhibiting one enzyme simultaneously raises two separate metabolic pools (NAD+ and SAM) with major downstream effects</li>
              <li>NNMT elevation in obese adipose tissue is a consistent finding that suggests it may be a genuine driver of the obese metabolic phenotype, not just a correlate</li>
              <li>Oral administration removes the injection barrier present with most research compounds in this space</li>
              <li>An active area of academic metabolic research even if community use has outpaced the science</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
